Streetbeat News

Regulatory

DADA

Dada Nexus announced that its net revenues and operations and support costs were overstated in past financial statements, affecting four quarters from Q4 2022 to Q3 2023. The overstatements ranged from RMB40 million to RMB245 million for revenues and RMB42 million to RMB250 million for costs.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:57 pm

FITB

Fifth Third Bancorp announced in an SEC filing that it is not pursuing new office commercial real estate (CRE) originations and expects to continue generating savings into 2024 and beyond.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:55 pm

TXO

TXO Partners LP has filed for a mixed shelf offering of up to $250 million, according to an SEC filing. Additionally, there is an offering of up to 11.5 million common units by the selling unitholders.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:53 pm

DXCM

DexCom's stock is trading higher following the announcement of FDA clearance for its product, Stelo. This regulatory approval marks a significant milestone for DexCom, potentially enhancing its market position and product portfolio.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:52 pm

FHTX

Foghorn Therapeutics Inc. (FHTX) announced its participation in the 2024 AACR Annual Meeting with presentations on its pipeline programs, including preclinical data for FHD-909, a potential first-in-class BRM selective inhibitor. The company will present data on the efficacy and safety of FHD-909 and other programs such as selective CBP and EP300 degraders, showcasing significant anti-tumor activity and long-acting degrader capabilities for up to once-a-month dosing. IND filing for FHD-909 is planned in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:51 pm

CRBU

Caribou Biosciences, Inc. (NASDAQ:CRBU) announced it will present preclinical data on CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for r/r AML, at the AACR Annual Meeting 2024. CB-012, engineered with Caribou's CRISPR technology, shows promise in improving antitumor activity through unique genome edits.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:38 pm

INAB

IN8bio will present new preclinical data at AACR Annual Meeting 2024, showing proof-of-concept for its gamma-delta CAR platform candidate targeting CD-33 and CD-123. This platform can target cancer cells while sparing healthy tissue, potentially treating previously 'undruggable' tumors.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:32 pm

DXCM

The FDA has cleared Stelo, a glucose biosensor by Dexcom, for over-the-counter use in the US. It's designed for individuals 18 and older with Type 2 diabetes not on insulin therapy. Stelo, a small wearable sensor, provides glucose insights directly to a smartphone and is set to be available in summer 2024.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:29 pm

SPY

USO

U.S. National Security Advisor Sullivan met with the Prime Minister of Qatar to discuss efforts aimed at securing the release of hostages held by Hamas, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:01 pm

FXI

SPY

Republican Senator Rubio proposes a new $20,000 tariff on vehicles produced by Chinese automakers, potentially impacting trade relations and the automotive industry.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 8:07 pm